Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab. Based on past history with data discrepancy, this approval acted as a huge relief for the company. Investors have been recommended to stay alert of updates, as this potential product would be Peregrine’s first to be released to market.
View the full article here (http://www.zacks.com/stock/news/100094/encouraging-news-for-peregrine-pharma-).
Categories: cancer, COMPANIES, The Healthcare Investor
